The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Athauda, Dilan, Foltynie, Thomas·2016·Drug Discovery Today

DOI 10.1016/j.drudis.2016.01.013

Cited by (383)

Items 101–200 of 383

Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury
Ian A. Tamargo, Miaad Bader, Yazhou Li, Seong‐Jin Yu, Yun Wang, Konrad Talbot, Richard D. DiMarchi, Chaim G. Pick, Nigel H. Greig · 2016 · Experimental Neurology
Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease
Dongliang Lv, Peng Feng, Xueying Guan, Zewei Liu, Dongfang Li, Cunshui Xue, Bo Bai, Christian Hölscher · 2024 · Frontiers in Neurology
Enteroendocrine cells: the gatekeepers of microbiome-gut-brain communication
Esmée Grundeken, Sahar El Aidy · 2025 · npj Biofilms and Microbiomes
Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression—A Literature Review
Young Sup Woo, Hyun Kook Lim, Sheng‐Min Wang, Won‐Myong Bahk · 2020 · International Journal of Molecular Sciences
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes: A Target Trial Emulation Study
Tang, Huilin, Lu, Ying, Donahoo, William T., Shao, Hui, Shi, Lizheng, Fonseca, Vivian A., Guo, Yi, Bian, Jiang, Guo, Jingchuan · 2024 · Annals of Internal Medicine
Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma
Emily C. N. Lawrence, Michelle Guo, Turner D. Schwartz, Jie Jayne Wu, Jingwen Lu, Sergei S. Nikonov, Jacob K. Sterling, Qi N. Cui · 2023 · Frontiers in Cellular Neuroscience
Peptide RL-QN15 promotes wound healing of diabetic foot ulcers through p38 mitogen-activated protein kinase and smad3/miR-4482-3p/vascular endothelial growth factor B axis
Dandan Sun, Kun Guo, Naixin Liu, Yilin Li, Yuansheng Li, Yan Wei Hu, Shanshan Li, Zhe Fu, Yinglei Wang, Yutong Wu et al. · 2023 · Burns & Trauma
Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1
Ahmed M. Kabel, Mohamed S. Omar, A. Alhadhrami, Salman S. Alharthi, Majed Alrobaian · 2018 · Physiology & Behavior
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs
Andreas P. Katsenos, Athena S. Davri, Yannis Vasileios Simos, Ilias P. Nikas, Chryssa Bekiari, Stavroula Α. Paschou, Dimitrios Peschos, Spyridon Konitsiotis, Patra Vezyraki, Konstantinos Ioannis Tsamis · 2021 · Expert Opinion on Investigational Drugs
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model
Li, Lin, Zhang, Ling-Yu, Jin, Qian-Qian, Hölscher, Christian · 2021 · Neural Regeneration Research
Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology
Antonella Tramutola, Andrea Arena, Chiara Cini, David Allan Butterfield, Eugenio Barone · 2016 · Expert Review of Neurotherapeutics
Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation
André Rodrigues da Cunha Barreto Vianna, Márcia Barbosa Águila, Carlos Alberto Mandarim‐de‐Lacerda · 2017 · Metabolic Brain Disease
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)
Andrea Sturchio, Luca Marsili, Joaquín A. Vizcarra, Alok Kumar Dwivedi, Marcelo Kauffman, Andrew P. Duker, Peixin Lu, Michael W. Pauciulo, Benjamin D. Wissel, Emily J. Hill et al. · 2020 · Frontiers in Aging Neuroscience
Comprehensive Review on Potential Signaling Pathways Involving the Transfer of α-Synuclein from the Gut to the Brain That Leads to Parkinson’s Disease
Shobha Kumari, Rajeev Taliyan, Sunil Kumar Dubey · 2023 · ACS Chemical Neuroscience
Strategies targeting endoplasmic reticulum stress to improve Parkinson’s disease
Danni Wang, Shuhui Qu, Zaijun Zhang, Liang Tan, Xiuping Chen, Hai‐Jing Zhong, Cheong‐Meng Chong · 2023 · Frontiers in Pharmacology
A Systematic Review of Semaglutide’s Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies
Raluca Oana Tipa, Daniela-Gabriela Bălan, Mihai Géorgescu, Luciana Angela Ignat, Ileana Adela Văcăroiu, Dragos Eugen Georgescu, Laura Răducu, Doina Andrada Mihai, Liviu Vasile Chiperi, Andra-Elena Balcangiu‐Stroescu · 2024 · International Journal of Molecular Sciences
The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Elisa Menozzi, Anthony H.V. Schapira, Per Borghammer · 2025 · Movement Disorders Clinical Practice
Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
Shuyi Wang, Shey‐Lin Wu, Ta-Cheng Chen, Chieh‐Sen Chuang · 2020 · International Journal of Environmental Research and Public Health
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, Iva, Matasin, Marija, Turk, Viktorija Erdeljic, Salković-Petrisic, Melita · 2022 · Journal of Neural Transmission
Novel Targets for Parkinson’s Disease: Addressing Different Therapeutic Paradigms and Conundrums
Pallavi Rane, Deepaneeta Sarmah, Shashikala Bhute, Harpreet Kaur, Avirag Goswami, Kiran Kalia, Anupom Borah, Kunjan R. Dave, Nutan Sharma, Pallab Bhattacharya · 2018 · ACS Chemical Neuroscience
Plant Polyphenols and Exendin-4 Prevent Hyperactivity and TNF-α Release in LPS-Treated In vitro Neuron/Astrocyte/Microglial Networks
Francesca Gullo, Michela Ceriani, Alessia D’Aloia, Enzo Wanke, Andrew Constanti, Barbara Costa, Marzia Lecchi · 2017 · Frontiers in Neuroscience
Sustained Release GLP‑1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease
Vicki Wang, Tung‐Tai Kuo, Eagle Yi‐Kung Huang, Kuo‐Hsing Ma, Yu‐Ching Chou, Zhao-Yang Fu, Li-Wen Lai, Jin Ho Jung, Hoi-II Choi, Doo‐Sup Choi et al. · 2021 · ACS Pharmacology & Translational Science
Investigating the Glucagon-like Peptide-1 and Its Receptor in Human Brain: Distribution of Expression, Functional Implications, Age-related Changes and Species Specific Characteristics
Tulika Gupta, Mandeep Kaur, Devendra Shekhawat, Ritu Aggarwal, Neha Nanda, Daisy Sahni · 2021 · Basic and Clinical Neuroscience Journal
Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
Miaad Bader, Yazhou Li, Daniela Lecca, Vardit Rubovitch, David Tweedie, Elliot J. Glotfelty, Lital Rachmany, Hee Kyung Kim, Hoil Choi, Barry J. Hoffer et al. · 2018 · Neurobiology of Disease
Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson’s Disease
Dong Dong, Jun-Xia Xie, Jun Wang · 2019 · Neuroscience Bulletin
Protective effect of alogliptin against cyclophosphamide-induced lung toxicity in rats: Impact on PI3K/Akt/FoxO1 pathway and downstream inflammatory cascades
Amira Ebrahim Alsemeh, Doaa M. Abdullah · 2022 · Cell and Tissue Research
Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
Qi Cheng, Jinluo Cheng, Dennis John Cordato, Jianqun Gao · 2020 · Pharmacology & Therapeutics
Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
Bruno Dutra Arbo, Lúcia Emanueli Schimith, Michele Goulart dos Santos, Mariana Appel Hort · 2022 · European Journal of Pharmacology
Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke
Yazhou Li, Kou‐Jen Wu, Seong‐Jin Yu, Ian A. Tamargo, Yun Wang, Nigel H. Greig · 2016 · Experimental Neurology
Delayed Administration of the Glucagon-Like Peptide 1 Analog Liraglutide Promoting Angiogenesis after Focal Cerebral Ischemia in Mice
Chen, Yanxia, Zhang, Xiangjian, He, Junna, Xie, Yanzhao, Yang, Yang · 2018 · Journal of Stroke and Cerebrovascular Diseases
Beyond Dopamine: Novel Therapeutic Pathways for Parkinson's Disease Through Receptor Signaling
Rashmi Bhushan, Falguni Goel, Shamsher Singh · 2025 · CNS & Neurological Disorders - Drug Targets
The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases
Grażyna Söderbom, Bai‐Yun Zeng · 2020 · International review of neurobiology
Hormonal Regulation of Oxidative Phosphorylation in the Brain in Health and Disease
Katarzyna Głombik, Jan Detka, Bogusława Budziszewska · 2021 · Cells
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
Holly Green, Panagiota Tsitsi, Ioanna Markaki, Dag Aarsland, Per Svenningsson · 2019 · CNS Drugs
Association Between Diabetic Retinopathy and Parkinson Disease: The Korean National Health Insurance Service Database
Seung Eun Lee, Kyungdo Han, Ji Yeon Baek, Kyung Soo Ko, Ki‐Up Lee, Eun Hee Koh · 2018 · The Journal of Clinical Endocrinology & Metabolism
Neurotrophic, anti-neuroinflammatory, and redox balance mechanisms of chalcones
Temitope Isaac Adelusi, Gbemisola Rebecca Akinbolaji, Xiaoxing Yin, Kehinde Sulaimon Ayinde, Olamide Tosin Olaoba · 2020 · European Journal of Pharmacology
Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies
Sango, Kazunori, Takaku, Shizuka, Tsukamoto, Masami, Niimi, Naoko, Yako, Hideji · 2022 · Frontiers in Cell and Developmental Biology
Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases
Yanwei Li, Lin Li, Christian Hölscher · 2016 · Reviews in the Neurosciences
Gastrointestinal hormones in regulation of memory
Anwesha Mandal, Kedar S. Prabhavalkar, Lokesh Kumar Bhatt · 2018 · Peptides
Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration
Mehan, Sidharth, Bhalla, Sonalika, Siddiqui, Ehraz Mehmood, Sharma, Nidhi, Shandilya, Ambika, Khan, Andleeb · 2022 · Degenerative Neurological and Neuromuscular Disease
Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium
Thomas J. Guttuso, Kelly L. Andrzejewski, David Gordon Lichter, Julie Kay Andersen · 2019 · Journal of the Neurological Sciences
The Neurotrophic Function of Glucagon-Like Peptide-1 Promotes Human Neuroblastoma Differentiation via the PI3K-AKT Axis
Jenq‐Lin Yang, Yu-Ting Lin, Wei‐Yu Chen, Yunru Yang, Shu‐Fang Sun, Shang‐Der Chen · 2020 · Biology
Research on developing drugs for Parkinson's disease
Chenglu Zhang, Qi-wen Han, Nai‐Hong Chen, Yu‐He Yuan · 2020 · Brain Research Bulletin
Diabetes, insulin and new therapeutic strategies for Parkinson’s disease: Focus on glucagon-like peptide-1 receptor agonists
Carmen M. Labandeira, Arturo Fraga Bau, David Arias Ron, Ana Muñoz, G. Alonso Losada, Antonio Koukoulis, J Romero-López, Ana Isabel Rodriguez-Perez · 2021 · Frontiers in Neuroendocrinology
The promise of GLP-1 receptor agonists for neurodegenerative diseases
Dilan S. Athauda, Nigel H. Greig, Wassilios G. Meissner, Thomas Foltynie, Sonia Gandhi · 2026 · Journal of Clinical Investigation
Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications
Yaswanth Kuthati, Venkata Naga Goutham Davuluri, Chih‐Shung Wong · 2025 · Biomolecules
Neuroprotective efficacy of 4-Hydroxyisoleucine in experimentally induced intracerebral hemorrhage
Ehraz Mehmood Siddiqui, Sidharth Mehan, Shubham Upadhayay, Andleeb Khan, Maryam Halawi, Azhar Ahmed Halawi, Rana M. Alsaffar · 2021 · Saudi Journal of Biological Sciences
Function and therapeutic value of astrocytes in diabetic cognitive impairment
Fanyu Meng, Jiafeng Fu, Lin Zhang, Mengqing Guo, Pengwei Zhuang, Qingsheng Yin, Yanjun Zhang · 2023 · Neurochemistry International
DPP4 Inhibitors Can Be a Drug of Choice for Type 3 Diabetes: A Mini Review
Nehru Sai Suresh Chalichem, Chaitanya Gonugunta, Praveen Thaggikuppe Krishnamurthy, Duraiswamy Basavan · 2017 · American Journal of Alzheimer s Disease & Other Dementias®
Treatment of Depression with Acupuncture Based on Pathophysiological Mechanism
Bo Sun, Xue‐Wei Cao, Ming Xin, Ruiqian Guan · 2024 · International Journal of General Medicine
Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer’s disease
Yuka Ikeda, Nozomi Nagase, Ai Tsuji, Yasuko Kitagishi, Satoru Matsuda · 2021 · World Journal of Biological Chemistry
Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review
Xin Jian Jiang, Ji Li, Xiaohui Yao, Hao Ding, Aihong Gu, Zhen Zhou · 2024 · Frontiers in Pharmacology
Old wines in new bottles: Repurposing opportunities for Parkinson's disease
Ashish Kumar Kakkar, Harmanjit Singh, Bikash Medhi · 2018 · European Journal of Pharmacology
DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects
Gang Zhang, Samuel Kim, Xiaohuan Gu, Shan Ping Yu, Ling Wei · 2019 · Neuroscience Bulletin
Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry
Wilfredo López-Ojeda, Robin A. Hurley · 2024 · Journal of Neuropsychiatry
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhidong Zhou, Ling Yi, Karolina Popławska-Domaszewicz, К. Ray Chaudhuri, Joseph J. Jankovic, Eng King Tan · 2025 · Pharmacological Research
A systematic review on type 3 diabetes: bridging the gap between metabolic dysfunction and Alzheimer’s disease
Fereshteh Atabi, Mahdi Moassesfar, Tara Nakhaie, Mobina Bagherian, Niloufar Hosseinpour, Mehrdad Hashemi · 2025 · Diabetology & Metabolic Syndrome
Long-term functional alterations following prenatal GLP-1R activation
Devon L. Graham, Haley S. Madkour, Brenda L. Noble, Christopher W. Schatschneider, Gregg D. Stanwood · 2021 · Neurotoxicology and Teratology
The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase
Vera Battini, Robbert P. van Manen, Michele Gringeri, Giulia Mosini, Greta Guarnieri, Anna Bombelli, Marco Pozzi, Maria Nobile, Sonia Radice, Emilio Clementi et al. · 2023 · Frontiers in Pharmacology
Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change
Shahin Hallaj, William Halfpenny, Benton Chuter, Robert Neal Weinreb, Sally L. Baxter, Qi N. Cui · 2024 · American Journal of Ophthalmology
Glucose signaling in the brain and periphery to memory
Md. Shamim Hossain, Yutaka Oomura, Takehiko Fujino, Koichi Akashi · 2020 · Neuroscience & Biobehavioral Reviews
GLP-1 and GIP receptor agonists in the treatment of Parkinson’s disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies
Carolina Vaccari, Denise Grotto, Tiago da Veiga Pereira, João Lauro Viana de Camargo, Luciane Cruz Lopes · 2021 · PLoS ONE
Myeloid cells in retinal and brain degeneration
Michelle Guo, Turner D. Schwartz, Joshua L. Dunaief, Qi N. Cui · 2021 · FEBS Journal
Regulation of neuroinflammation with GLP-1 receptor targeting nanostructures to alleviate Alzheimer’s symptoms in the disease models
Yipeng Zhao, Siyu Tian, Jie Zhang, Xi Cheng, Wenping Huang, Guoliang Cao, Yan‐Zhong Chang, Hai Wang, Guangjun Nie, Wei Qiu · 2022 · Nano Today
Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson's disease
Kinjal V Abhangi, Jigneshkumar I. Patel · 2022 · Indian Journal of Pharmacology
Dipeptidyl peptidase 4(DPP4) inhibitors stride up the management of Parkinson's disease
Maanvi, Shilpa Kumari, Rahul R Deshmukh · 2022 · European Journal of Pharmacology
The role of GLP-1/GIP receptor agonists in Alzheimer’s disease
Chun Jiang Yu, Ling ling Song, Zhen nan Zhai, Ye Tao, Y. Zhang, Ling yu Cai, Ya hui Hou, Hong yuan Chen, Li Wang · 2020 · Advances in Clinical and Experimental Medicine
Targeting astrocytes polarization after spinal cord injury: a promising direction
Helin Li, Ying Liu, Yucao Sun, Hangyu Guo, Shiyan Lv, Wenhui Guo, Jiyu Ren, Yufu Wang, Jianing Zu, Jinglong Yan et al. · 2024 · Frontiers in Cellular Neuroscience
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Ahmed Tanvir, Junghyun Jo, Sang Myun Park · 2024 · Cells
Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer’s Disease
Abhilasha Ahlawat, Vaibhav Walia, Munish Garg · 2025 · Acta Neurologica Belgica
Gut-Brain Communication in Parkinson’s Disease: Enteroendocrine Regulation by GLP-1
Richard A. Manfready, Christopher B. Forsyth, Robin M. Voigt, Deborah A. Hall, Christopher G. Goetz, Ali Keshavarzian · 2022 · Current Neurology and Neuroscience Reports
Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice
Vicki Wang, Kuan-Yin Tseng, Tung‐Tai Kuo, Eagle Yi‐Kung Huang, Kuo-Lun Lan, Zirong Chen, Kuo‐Hsing Ma, Nigel H. Greig, Yoo Jin Jung, Ho-II Choi et al. · 2024 · Journal of Biomedical Science
The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders
Jenq‐Lin Yang, Wei‐Yu Chen, Shang‐Der Chen · 2017 · International Journal of Molecular Sciences
Possible role of DPP4 inhibitors to promote hippocampal neurogenesis in Alzheimer’s disease
Nehru Sai Suresh Chalichem, Sai Kiran S. S. Pindiprolu, Duraiswamy Basavan · 2018 · Journal of drug targeting
Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson’s Disease
Marco Sancandi, Emma Victoria Schul, Georgia Economides, Andrew Constanti, Audrey Mercer · 2018 · Frontiers in Cellular Neuroscience
Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease
Jelena Osmanović Barilar, Ana Knezović, Ana Babić Perhoč, Jan Homolak, Peter Franz Riederer, Melita Šalković‐Petrišić · 2020 · Journal of Neural Transmission
Prospects for Disease Slowing in Parkinson Disease
Elisa Menozzi, Anthony H.V. Schapira · 2024 · The Annual Review of Pharmacology and Toxicology
Beyond metabolic messengers: Bile acids and TGR5 as pharmacotherapeutic intervention for psychiatric disorders
Arief Gunawan Darmanto, Ting‐Lin Yen, Jing‐Shiun Jan, Tran Thanh Duy Linh, Rajeev Taliyan, Chih Hao Yang, Joen‐Rong Sheu · 2024 · Pharmacological Research
Impact of Nutrition, Microbiota Transplant and Weight Loss Surgery on Dopaminergic Alterations in Parkinson’s Disease and Obesity
Sevag Hamamah, András Sándor Hajnal, Mihai Covașă · 2022 · International Journal of Molecular Sciences
Type 2 Diabetes Mellitus Exacerbates Pathological Processes of Parkinson's Disease: Insights from Signaling Pathways Mediated by Insulin Receptors
Shufen Liu, Tingting Liu, Jingwen Li, Jun Hong, Ali Akbar Moosavi‐Movahedi, Jianshe Wei · 2025 · Neuroscience Bulletin
Linagliptin attenuates thioacetamide-induced hepatic encephalopathy in rats: Modulation of C/EBP-β and CX3CL1/Fractalkine, neuro-inflammation, oxidative stress and behavioral defects
Yosra Assem Hussien, Dina Farouk Mansour, Somaia Ahmed Nada, Sahar S. Abd El‐Rahman, Rania M. Abdelsalam, Amina Salem Attia, Dalia M. El-Tanbouly · 2022 · Life Sciences
Citronellol Prevents 6-OHDA-Induced Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis in Parkinson Disease Model of SH-SY5Y Cells via Modulating ROS-NO, MAPK/ERK, and PI3K/Akt Signaling Pathways
Jiahui Shao, Xuan Liu, Mengjia Lian, Youbing Mao · 2022 · Neurotoxicity Research
Non-protein biologic therapeutics
Susan T. Sharfstein · 2017 · Current Opinion in Biotechnology
Hearing Damage Induced by Blast Overpressure at Mild TBI Level in a Chinchilla Model
Kyle D. Smith, Tao Chen, Rong Z. Gan · 2020 · Military Medicine
Clinical Trial Highlights – GLP-1 agonists
Kevin McFarthing, Danielle Larson, Tanya Simuni · 2020 · Journal of Parkinson s Disease
Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System
He Chen, Sixing Liu, Shuai He Gao, Hangyu Shi, Yan Yan, Yixing Xu, Jiufei Fang, Weiming Wang, Huan Chen, Zhishun Liu · 2025 · Scientific Reports
Alogliptin: a novel approach against cyclophosphamide-induced hepatic injury via modulating SIRT1/FoxO1 pathway
Rania M. Salama, Abdelkader M Mohamed, Nada S Hamed, Raneem M Ata, Amira S NourelDeen, Mohamed Hassan · 2020 · Toxicology Research
Attenuated Postprandial GLP-1 Response in Parkinson’s Disease
Richard A. Manfready, Phillip A. Engen, Leo Verhagen Metman, Gabriella Sanzo, Christopher G. Goetz, Deborah A. Hall, Christopher B. Forsyth, Shohreh Raeisi, Robin M. Voigt, Ali Keshavarzian · 2021 · Frontiers in Neuroscience
A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease
Laura Poupon-Bejuit, Michael P. Hughes, Wenfei Liu, Amy F. Geard, N. Faour-Slika, Sammie M Whaler, Giulia Massaro, Ahad A. Rahim · 2022 · Scientific Reports
Targeting G Protein-Coupled Receptors in the Treatment of Parkinson's Disease.
J. Jones-Tabah · 2022 · Journal of Molecular Biology
Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson’s and Alzheimer’s Disease
Cameron Noah Keighron, Sahar Avazzadeh, Katarzyna Goljanek‐Whysall, Brian McDonagh, Linda Howard, Thomas Ritter, Leo R. Quinlan · 2023 · Biomedicines
GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer's disease pathology and treatment
Neha Neha, Zitin Wali, Pinky Pinky, Shaheenkousar H. Hattiwale, Azfar Jamal, Suhel Parvez · 2023 · Ageing Research Reviews
Kolaviron protects against nigrostriatal degeneration and gut oxidative damage in a stereotaxic rotenone model of Parkinson’s disease
Ebenezer O. Farombi, Ifeoluwa Oluleke Awogbindin, Precious D. Olorunkalu, Emmanuel Ogbuewu, Bisola F. Oyetunde, Alberta E. Agedah, Philip Adeyemi Adeniyi · 2020 · Psychopharmacology
Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs
Mojca Lunder, Miodrag Janić, Mišo Šabović · 2021 · International Journal of Molecular Sciences
The Role of Astrocytes and Alpha-Synuclein in Parkinson’s Disease: A Review
David Brash-Arias, Luis I. García, César Antonio Pérez-Estudillo, Fausto Rojas-Durán, Gonzálo Emiliano Aranda-Abreu, Deissy Herrera‐Covarrubias, Donají Chi-Castañeda · 2024 · NeuroSci
Targeting Altered Mitochondrial Biogenesis in the Brain of Diabetic Rats: Potential Effect of Pioglitazone and Exendin-4
Ola M. Tork, Laila Ahmed Rashed, Nermeen Bakr Sadek, Marwa Sayed Abdel-Tawab · 2019 · PubMed Central
Liraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways
Lan Yang, Junmin Cheng, Guang Shi, Cong Zhang, Yuanyuan Du, Linyu Chen, Huimin Qiao, Rong Chen, Xiangjian Zhang · 2022 · Neurochemical Research
Attenuation of diabetic kidney injury in DPP4-deficient rats; role of GLP-1 on the suppression of AGE formation by inducing glyoxalase 1
Mithun Kumer Sarker, Jong Han Lee, Dae Ho Lee, Kwang‐Hoon Chun, Hee‐Sook Jun · 2020 · Aging
Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
Zhixuan Xie, Zuyi Yang, Dianzhe Tian, Youxin Chen · 2025 · Frontiers in Pharmacology
Brain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET
Laura N. Deden, Jan Booij, Joanes Grandjean, Judith Regina Homberg, Eric J. Hazebroek, Martin Gotthardt, Marti Boss · 2021 · Brain Sciences